
## Local Management of Diabetic Foot Ulcers (DFU)

Guideline Summary

WORLD UNION OF WOUND HEALING SOCIETIES







### Content

Epidemiology and Risk Factors of DFU
Definition of DFU
Assessment of DFU
Aetiology of Indication
Management & Strategy of DELL
Management & Strategy of DFU
T.I.M.E. Framework of DFU
Overview of Local Wound Management
Other Considerations in Local Wound Management
Overview of Treatment Recommendations for Special Considerations by HARTMANN

This summary has been prepared by PAUL HARTMANN AG and its sole purpose is to support healthcare professionals only. It does not include the full text of the original publication and PAUL HARTMANN AG makes no representation as to its completeness in detailing all content of the publication on which it is based.

# Epidemiology and Risk Factors of DFU

### Epidemiology

#### **Global facts and figures**

Incidence of diabetes has almost quadrupled in the past 30 years with 422 million adults worldwide now diagnosed.

- Global prevalence has increased from 4.7-8.5%
- Incidence of DFU among diabetics is 4–10%
- 1-in-4 risk of ulceration during a lifetime

#### A patient with DFU has

- an increased risk of hospitalization due to infection a high risk of amputation
- a high risk of a further amputation in less than 3 years after the first amputation
- higher mortality rate (greater than the 5-year mortality rate of breast, colon and prostate cancer combined)

A person with diabetes has a 25% risk to develop DFU

2

3

3

3

4

4

8

8



### Definitions of DFU

#### **Diabetic foot**

Infection, ulceration or destruction of tissues of the foot associated with neuropathy and/or peripheral artery disease in the lower extremity

of people with diabetes.

#### **Diabetic foot lesion**

Abnormalities associated with damage to the skin, nails or deep tissues

of the foot.

#### **Diabetic foot ulcer**

Full thickness lesion of the diabetic foot. May be superficial (not penetrating any structure deeper than the dermis) or deep (penetrating below the dermis to subcutaneous structures, such as

fascia, muscle, tendon or bone).

### Assessment of DFU

#### **General assessment**

- Diabetes management and blood glucose control habits (smoking and substance abuse)
- Symptoms & signs of late complications
- Systemic sign of infection pain
- Socioeconomic circumstances, ...

#### Local treatment

- Characteristics of the leg
- Characteristics of the ulcer
- Loss of sensation
- Vascular assessment
- Presence of infection, ...

# Aetiology of Indication





#### Neuropathic

Impaired sensitivity of the foot (unnoticed injuries)

Abnormal biomechanical loading of the foot (foot deformities, callus formation)

- Dry skin, fissuring, cracking
- Warm foot, bounding pulses
- On plantar aspect of the foot and of the toes



#### Ischemic

Mostly due to PAD (Peripheral Artery Disease)

Minority of all DFUs (10–15%)

- Pale, shinny skin, lack of hair
- Cool foot, absent pulses
- Punched out wounds, demarcated edges
- Over the toes, heels, and bony prominences of the foot



#### **Neuro-Ischemic**

Combined by both neuropathy and ischemia

Majority of all DFUs

- on the tips of the toes and
- Present with necrosis and are prone to infection

• Located on margins of the foot, beneath thickened toe nails

## Management & Strategy of DFU

### Management

#### Wound closure

Ultimate goal

#### If not realistic (e.g. palliative patient), need re-adjustment:

- Prevention of infection
- Management of exudate
- Odour, pain, improved quality of life, simplified wound dressing procedures

#### **Prevention of recurrence**

- Role of protective footwear, patient education and regular foot examination
- Dressings (film, hydrocolloid, foam) may be used for 1–2 weeks after wound closure for protection

#### Limb preservation

- Multifactorial treatment
- Multidisciplinary approach
- Preventive strategy
- Patient and staff education may decrease amputation rate by more than 50%

### Strategies<sup>1,2</sup>

### Treatment of underlying disease

- All comorbidities must be treated
- Multidisciplinary team

### Establishment of adequate blood supply

- Conservative treatment
- Surgical revascularization


#### **Pressure offloading**


- Total contact casts
- Removable cast walkers...

#### Local wound care

- Total contact casts
- T.I.M.E. framework recommended

### T.I.M.E. Framework of DFU<sup>1,2</sup>





### Non-viable, deficient tissue **Cleansing & Debridement**

Allows removal of necrotic, senescent tissues, foreign and infected materials from a wound.

Clean drinking water or saline solution may be used for cleaning.

Antiseptic solutions for cleaning controversial – to be used with caution, where benefits greatly outweigh possible detrimental effects on wound tissues.

#### **Effects**

Decreases bacterial counts

Stimulates production of growth factors

Reduces pressure

Allows inspection & evaluation of the wound bed

Facilitates wound drainage

Stimulates healing

#### Many debridement methods available

#### **Sharp debridement**

Most common, requires experienced practitioners with specialist training (in order to distinguish tissue types, avoid damage to blood vessels, nerves and tendons). Is an invasive, often radical procedure.

#### Autolytic debridement

Popular method, based on a natural process that uses a moist wound dressing to soften and remove devitalized tissue.

#### Other methods available

Surgical, enzymatic, larval...

**Debridement should be repeated as necessary** (mantainance debridement).



\*Cover dry until appropriate vascular assessment and corrective measures

#### Autolytic debridement

Selective debridement by release of patient's own proteolytic enzymes and phagocytes cells which soften and break down necrotic and sloughy tissue, removed at subsequent dressing changes.

Dual mode of action: Wound dressings which provide autolytic debridement and at the same time donate fluid to the wound bed and absorb excessive tissue-damaging wound exudate components (e.g., proteinases such as Matrix Metallproteinases (MMPs).



HydroClean<sup>®</sup> plus plays an important role in aiding autolytic debridement, significantly reducing necrotic/sloughy tissue.<sup>3,4</sup>



### Inflammation & infection control

#### If inflammation and infection is present, main strategies focus on

Decreasing inflammatory cytokines and protease activity

Decreasing bacterial burden

Treatment of infection

#### **Cleansing**, **debridement**!

#### **Antimicrobial dressings?**

Infection present In combination with systemic antibiotics.

Increased bacterial burden May reduce bacterial load and prevent spread of bacteria to deeper tissues.

#### HydroClean<sup>®</sup> plus

HydroClean<sup>®</sup> plus supports cleaning and debridement, removes factors involved in infectionand assists with inflammation (including MMPs) control.<sup>5,6,7</sup>





2-weeks rule Re-evaluate effectiveness.

### Moisture balance M

#### **Strategies to create** moisture balance include

Absorption of exudate

Mantainance of moist environment

Prevention of maceration

Mantainance of clean wound bed

- Promotes further autolysis of slough  $[\searrow$ 
  - Supports cell migration and proliferation
- Encourages growth factors activity  $\bigotimes$



\*Dressings and their frequency of change have to be complementary to the compression therapy

#### HydroClean<sup>®</sup> plus

HydroClean<sup>®</sup> balances moisture by its Rinsing-Absorption-Mechanism.<sup>4,8</sup> HydroTac<sup>®</sup> selectively absorbs and donates moisture according to the wound needs.<sup>4,9,10</sup>





If epithelialization is impaired, re-assessment and re-adjustment of T.I.M. strategies are needed.

#### Advanced technologies to consider

#### HydroTac<sup>®</sup> (part of HydroTherapy)<sup>9,11</sup>

Increases growth factor concentration

Boosts epithelialization


#### **Other advanced dressings**

Collagen dressings, bioengineered tissue products



### Overview of Local Wound Management

(by HARTMANN according to T.I.M.E. framework)



			E
Je	Inflammation	Moisture	Impaired
	and/or infection	imbalance	epithelializat
	Decrease bacterial	Absorb excess	Reassess T.I.
	burden inflammatory	exudate, hydrate	Support
	cytokines, MMPs**	wound bed	epithelializat
	<image/>	<section-header></section-header>	<section-header></section-header>

#### d ation

T.I.M. rt ation



### Other Considerations in Local Wound Management

#### **Dressing fixation and change frequency**

Considering risk of constriction and further damage due to ischemia and/or fragile skin – avoid strong bandaging and strong adhesives

Frequent inspection, especially if wound is infected

Dressing must be suitable for use under the off-loading device

#### Pain and odour

Address the cause (infection? putrefaction of necrotic tissue? dressing?)


Use pain medication if needed, appropriate dressing selection to reduce pain and odour

#### Peri-wound skin

Prevent skin maceration by protecting peri-wound skin and by choosing dressing with appropriate exudate absorption capacity

### Overview of Treatment Recommendations for Special Considerations by HARTMANN

Special Considerations	Strategy required	Our recomme
Dry ischemic wound	Cover dry until revasculariza- tion/Specialist recomendation	Zetuvit® E
Infection/high risk for infection	Consider antimicrobial dressing	Atrauman® A HydroClean®
Highly exudative wound	Highly absorbent dressing	Zetuvit® Plus Zetuvit® Plus S
Tunneled and pocket wounds	Alginate dressing	HydroClean® HydroClean®
Fragile epithelialized wound	Protect 1–2 weeks after wound closure	Atrauman <sup>®</sup> Sil + Zetuvit <sup>®</sup> Plu Hydrosorb <sup>®</sup> G HydroTac <sup>®</sup>
Fragile peri-wound skin	Protect peri-wound skin	Atrauman <sup>®</sup> Si



[1] EWMA, Wound bed preparation in practice, Position Document, 2004. [2] Wounds International, Best Practice Guidelines: Wound Management in DFU, 2013. [3] Atkin, L. and Ousey, K. (2016). Wound bed preparation: A novel approach using HydroTherapy. British Journal of Community Nursing 21 (Supplt. 12), pp. S23-S28. [4] Ousey, K. et al. (2016). HydroTherapy Made Easy. Wounds UK 12(4). [5] Spruce, P. et al. (2016). Introducing HydroClean® plus for wound-bed preparation: a case series. Wounds International 7(1), pp. 26-32. [6] Ousey, K. et al. (2016). Hydro-Responsive Wound Dressings simplify T.I.M.E. wound management framework. British Journal of Community Nursing 21(Supplt. 12), pp. S39-S49. [7] Humbert, P. et al. (2014). Protease-modulating polyacrylate-based hydrogel stimulates wound bed preparation in venous leg ulcers – a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology 28(12), pp. 1742-1750. [8] Apelqvist, J., Willy, C., Fagerdah, A.M. et al. (2017). Negative Pressure Wound Therapy overview, challenges and perspectives. J Wound Care, 26 (3), Suppl 3, S1–S113. [9] Smola, H. (2016). Simplified treatment options require high-performance dressings – from molecular mechanisms to intelligent dressing choices. EWMA 2016. Bremen, 11-13 May, 2016. [10] Spruce, P. et al. (2016). A case study series evaluation of HydroTac®. HydroTherapy Symposium: A New Perspective on Wound Cleansing, Debridement and Healing. London, 3 March, 2016. [11] Smola, H. et al. (2016). Hydrated polyurethane polymers to increase growth factor bioavailability in wound healing. HydroTherapy Symposium: A New Perspective on Wound Cleansing, Debridement and Healing. London, 3 March, 2016.

#### HARTMANN UK & Ireland

Unit P2 Parklands, Heywood Distribution Park Pilsworth Road, Heywood OL10 2TT

Phone: +44 (0) 1706 363200 | Fax: +44 (0) 1706 363201 | Email: info@uk.hartmann.info

#### www.hartmann.co.uk

©2019 Paul Hartmann Limited. ® represents a trademark of Paul Hartmann Limited, a company registered in England and Wales (company number 01523121) WM-00029/19-GB



